

Docket No. 260005USOPCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Pascale GAILLARD, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP03/04323

GAU:

FILED: Herewith

EXAMINER:

FOR: PIPERAZINE BENZOTHAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Richard L. Treanor

Registration No. 36, 379

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260005US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/EP03/04323	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Pascale GAILLARD, et al.			
				FILING DATE Herewith		GROUP	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AA	01/47920	07/05/01	WO		NO	
	AB	02/26711	04/04/02	WO		NO	
	AC	11-080155	03/26/99	JP(English abstract only)		NO	
	AD						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AE	Roger J. DAVIS, "Signal transduction by the JNK group of MAP kinases", CELL, vol. 103, pages 239-252 10/13/00					
	AF	Shashi GUPTA, et al., "Selective interaction of JNK protein kinase isoforms with transcription factors", THE EMBO JOURNAL, vol. 15, no. 11, pages 2760-2770 1996					
	AG	Calin D. DUMITRU, et al., "TNF- $\alpha$ induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway", CELL, vol. 103, pages 1071-1083 12/22/00					
	AH	Zuoning HAN, et al., "c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 1, pages 73-81, 2001					
	AI	Hiroshi NISHINA, et al., "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4(MKK4)-deficient T lymphocytes", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 6, pages 941-953 09/15/97					
	AJ	Stephan J. KEMPIAK, et al., "the jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the I $\kappa$ B kinase cascade", THE JOURNAL OF IMMUNOLOGY, vol. 162, pages 3176-3187 1999					
	AK	S. M. de la MONTE, et al., "Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells", JOURNAL OF ALZHEIMER'S DISEASE, vol. 2, pages 261-281 2000					
	AL	Xiongwei ZHU, et al., "Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease", JOURNAL OF NEUROCHEMISTRY, vol. 76, pages 435-441 2001					
	AM	Li XU, et al., "Assess the in vivo activation of signal transduction pathways with pathdetect reporting systems", STRATEGIES, vol. 11, pages 94-97 2001					
	AN	Mausumee GUHA, et al., "LPS induction of gene expression in human monocytes", CELLULAR SIGNALLING, vol. 13, pages 85-94 2001					
	AO	A. Jackie Hunter, et al., "Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs", TIPS, vol. 16, pages 123-128 1995					
	AP	F. BLOCK, "Global ischemia and behavioural deficits", PROGRESS IN NEUROBIOLOGY, vol. 58, pages 279-295 1999					
	AQ	Susan C. GERHARDT, et al., "Motor activity changes following cerebral ischemia in gerbils are correlated with the degree of neuronal degeneration in hippocampus", BEHAVIORAL NEUROSCIENCE, vol. 102, no. 2, pages 301-303 1988					
	AR	A. Lorris BETZ, et al., "Blood-brain-cerebrospinal fluid barriers", BASIC NEUROCHEMISTRY: MOLECULAR, CELLULAR, AND MEDICAL ASPECTS, 5 <sup>th</sup> edition, chapter 32, pages 681-699, 1994					
	AS	Gary W. GOLDSTEIN, et al., "The blood-brain barrier", SCIENTIFIC AMERICAN, pages 70-79 September 1986					
	AT						
	AU						<input type="checkbox"/> Additional References sheet(s) attached
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

New U.S. PCT Application Based on PCT/EP03/04323  
 Docket No.: 260005US0PCT

# STATEMENT OF RELEVANCY

- 1) References AA-AC have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of these references is being submitted herewith.
- 3) References AE-AS are discussed in the specification. A copy of these references is being submitted here with.
- 4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.